SCA
MRNA icon

Stonebridge Capital Advisors’s Moderna MRNA Stock Holding History

Stonebridge Capital Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-245
Closed -$25.3K – 589
2023
Q3 		$25.3K Hold
245
– – ﹤0.01% 460
2023
Q2 		$29.8K Hold
245
– – ﹤0.01% 438
2023
Q1 		$37.6K Sell
245
-5
-2% -$825 ﹤0.01% 404
2022
Q4 		$44.9K Hold
250
– – 0.01% 369
2022
Q3 		$30K Sell
250
-1
-0.4% -$152 ﹤0.01% 408
2022
Q2 		$36K Sell
251
-32
-11% -$4.57K ﹤0.01% 400
2022
Q1 		$49K Buy
283
+125
+79% +$21K 0.01% 393
2021
Q4 		$40K Buy
158
+1
+0.6% +$292 ﹤0.01% 405
2021
Q3 		$60K Sell
157
-143
-48% -$52.7K 0.01% 329
2021
Q2 		$55K Buy
300
+150
+100% +$26.8K ﹤0.01% 445
2021
Q1 		$20K Buy
+150
New +$21.7K ﹤0.01% 504

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Stonebridge Capital Advisors's MRNA Position: Q4 2023 in Review

Stonebridge Capital Advisors sold out of Moderna (MRNA) in Q4 2023, closing a stake of 245 shares — an estimated $25.3K sold.

Stonebridge Capital Advisors first reported a position in MRNA in Q1 2021 and held it in 11 quarters. The position peaked at $60K in Q3 2021. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • Stonebridge Capital Advisors reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • Stonebridge Capital Advisors sold 245 Moderna shares in Q4 2023, an estimated $25.3K.
  • Stonebridge Capital Advisors first reported a position in Moderna in Q1 2021 and held it in 11 quarters.
  • Stonebridge Capital Advisors's Moderna position peaked at $60K in Q3 2021.
  • 884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Stonebridge Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.